Skip to Content
Søg Menu

New Opportunities to Improve Care for People Living with Sickle Cell Disease

/ Jan Andreasen
ASH25
Johan Gustafsson

Towards Identifying Which CLL Patients with Richter Transformation Respond to Immune Checkpoint Inhibitor Therapy

/ Johan Gustafsson
ASH25 Play the Video 4:04
Shanga Hassan Qadir

Cladribine Effectiveness After Switching from DMTs - A Nationwide Danish Study

/ Shanga Hassan Qadir
ECTRIMS25 Play the Video 8:38

SABCS 2025: Favorable Benefit–Risk Profile of Sacituzumab Govitecan in Previously Untreated Metastatic TNBC PD-L1–ineligible Metastatic Triple-Negative Breast Cancer

/ Jan Andreasen
NBCNSABCS25Brystcancer

Higher-Than-Recommended Lenalidomide Dosing Is Safe in Transplant-Eligible Newly Diagnosed Multiple Myeloma with Renal Impairment

/ Frida Bugge Askeland / Jan Andreasen
ASH25Myelomatose

Hyperfraktioneret dosering for en mere individuel behandling [1]

/ Navamedic
Parkinsons

AML Insights – December Update: What’s New in the Field

/ Amanda Feldballe Bernholm / Jan Andreasen
AML

Nordic AML Insights - December Update

/ Amanda Feldballe Bernholm / Jan Andreasen
AML

Sustained Survival Benefit of Cemiplimab Plus Chemotherapy at 5 Years in Advanced NSCLC With PD-L1 ≥1%

/ Jan Andreasen
LungecancerImmunterapi

Kombination af enfortumab vedotin og pembrolizumab har forbedret behandlingen af blærecancer radikalt

/ Jakob Lauritsen / Jan Andreasen
Blærecancer
Back to top